Stem cell-derived therapy may be an avenue for treating Type 1 diabetes, according to a clinical trial by Vertex Pharmaceuticals.
The trial was centered on one patient, who was diagnosed with Type 1 diabetes 40 years ago. For decades, he had been dependent on insulin injections to manage his blood sugar.
Approximately 1.6 million Americans live with the disease, including about 200,000 young people under 20 years old, according to Juvenile Diabetes Research Foundation (JDRF), the leading global organization funding Type 1 diabetes research.
Type 1 diabetes is a disease that requires constant monitoring and management. People with Type 1 diabetes need to continually balance their insulin intake and measure blood-sugar levels by pricking their fingers at least six times a day or by wearing a glucose monitor, according to JDRF.